Drug Discovery & Development

Researchers ensure the success of their serial dilution-based assays by using optimized protocols and advanced liquid handling tools.

Learn how scientists examine mRNA quality using an easy-to-operate LC-MS system.

Learn how cutting-edge strategies empower researchers to target undruggable proteins.

The SmartChip ND system meets laboratories’ needs for flexibility, scalability, efficiency, and affordability.

A novel compound targets an essential transport system found only in disease-causing bacteria, leaving commensal bacteria unharmed. 

Nathalie Fuentes shared her experience of landing a unicorn position in a pharmaceutical company after a postdoctoral fellowship.

Harnessing the capabilities of the PhysioMimix Multi-organ System, the kit enhances lead optimization and preclinical testing pipelines, providing an all-in-one solution to generate predictive insights into human oral bioavailability, and better inform lead candidate selection.

Collaboration enables customers to securely and confidently use AI to accelerate drug research and discovery.

Discover how a precise, high-throughput proteomics assay enables researchers to uncover previously unidentified biomarkers.

Alexander Fleming’s 1928 discovery of a mold with antibacterial properties was only the first serendipitous event on the long road to penicillin as a life-saving drug.

Infrastructure expansion will enable rapid ingestion, homogenization of new multi-omics and real-world data for accelerated delivery of multidimensional insights to inform drug development

Explore how on-target precision therapies improve patient outcomes and drug tolerability.

Scientists modified Toxoplasma gondii to deliver a potential Rett Syndrome therapeutic to the mouse brain. 

Inhibiting a protein isoform in the spinal cord alongside morphine improves the opioid’s pain-relieving properties without increasing unwanted side effects.

Kevin Fitzgerald from Alnylam Pharmaceuticals explains the potential of RNA interference for treating disease and highlights recent clinical trial successes.

Learn more about Fluorescent Dyes from AAT Bioquest.

The extended agreement will expand the dedicated bioconjugation footprint for the customer through the construction of a new bioconjugation suite at Lonza’s Ibex^® Biopark in Visp (CH).

Advanced microscopy aided in the detection of the pathogen responsible for a nationwide superworm apocalypse and informed the development of a potential vaccine strategy.